Suppr超能文献

对于Masaoka-Koga IIB期胸腺瘤患者,根治性手术后进行术后放疗可能无法提高生存率:一项基于监测、流行病学和最终结果(SEER)数据库的倾向匹配研究。

Postoperative radiotherapy after extirpative surgery may not improve survival in patients with Masaoka-Koga stage IIB thymoma: a propensity-matched study based on the SEER database.

作者信息

Wang Hui, Guan Song, Liu Zheng, Li Yinpeng, Yan Jingjing

机构信息

Department of Respiratory and Critical Care, Hebei Petrochina Central Hospital, Langfang, China.

Department of Radiation Oncology, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Cancer Research Center, Capital Medical University, Beijing, China.

出版信息

J Thorac Dis. 2024 Oct 31;16(10):6381-6390. doi: 10.21037/jtd-24-1061. Epub 2024 Oct 30.

Abstract

BACKGROUND

The exact role of postoperative radiotherapy (PORT) in patients with Masaoka-Koga stage IIB thymoma following extirpative surgery (defined as radical surgery or total thymectomy) is still under debate. This study was designed to evaluate the effect of PORT on survival in patients with stage IIB thymoma following extirpative surgery in a population-based registry.

METHODS

Patients with Masaoka-Koga stage IIB thymoma who underwent extirpative surgery between 2000 and 2019 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. One-to-one propensity score matching (PSM) with Kaplan-Meier and Cox regression analyses were used to assess overall survival (OS) and cancer-specific survival (CSS). To identify potential patients who may benefit from PORT, exploratory subgroup analyses on survival and further analyses stratified by Asian patients were performed.

RESULTS

A total of 273 eligible patients were included, 164 (60.1%) in the PORT group and 109 (39.9%) in the non-PORT group. After 1:1 PSM, OS and CSS were not significantly different between the two groups. The 10-year OS and CSS rates were 83.5% in the PORT group 80.1% in the non-PORT group (P=0.95) and 97.8% 97.7% (P=0.31), respectively. The multivariate analyses further demonstrated no significant association between PORT and either OS [hazard ratio (HR) =1.219, P=0.53] or CSS (HR =2.304, P=0.32). Exploratory subgroup analyses revealed that PORT did not significantly improve survival in any subgroup of patients with stage IIB thymoma, and further analyses based on the Asian patients yielded the same negative results.

CONCLUSIONS

According to the SEER database, adding PORT to extirpative surgery may not improve survival in patients with Masaoka-Koga stage IIB thymomas.

摘要

背景

术后放疗(PORT)在接受根治性手术(定义为根治性手术或全胸腺切除术)的Masaoka-Koga IIB期胸腺瘤患者中的确切作用仍存在争议。本研究旨在评估基于人群登记的PORT对IIB期胸腺瘤患者接受根治性手术后生存的影响。

方法

从监测、流行病学和最终结果(SEER)数据库中识别出2000年至2019年间接受根治性手术的Masaoka-Koga IIB期胸腺瘤患者。采用一对一倾向评分匹配(PSM)、Kaplan-Meier分析和Cox回归分析来评估总生存期(OS)和癌症特异性生存期(CSS)。为了确定可能从PORT中获益的潜在患者,进行了生存探索性亚组分析,并按亚洲患者进行了进一步分层分析。

结果

共纳入273例符合条件的患者,PORT组164例(60.1%),非PORT组109例(39.9%)。1:1 PSM后,两组的OS和CSS无显著差异。PORT组的10年OS率和CSS率分别为83.5%和80.1%(P=0.95),97.8%和97.7%(P=0.31)。多变量分析进一步表明,PORT与OS[风险比(HR)=1.219,P=0.53]或CSS(HR =2.304,P=0.32)均无显著关联。探索性亚组分析显示,PORT在IIB期胸腺瘤患者的任何亚组中均未显著改善生存,基于亚洲患者的进一步分析也得出了相同的阴性结果。

结论

根据SEER数据库,在根治性手术基础上加用PORT可能无法改善Masaoka-Koga IIB期胸腺瘤患者的生存。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bf2/11565301/97b4e8125c09/jtd-16-10-6381-f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验